|
covid-19 vaccine |
39 |
|
sars-cov-2 |
39 |
|
covid-19 |
38 |
|
bnt162b2 |
29 |
|
coronavac |
29 |
|
vaccine safety |
29 |
|
covid-19 vaccines |
27 |
|
sars-cov-2 infection |
21 |
|
inactivated vaccine |
18 |
|
self-controlled case series |
18 |
|
long covid |
17 |
|
multimorbidity |
16 |
|
vaccine effectiveness |
15 |
|
epidemiology |
14 |
|
mortality |
14 |
|
diabetes |
12 |
|
innate immunity |
12 |
|
osteoporotic fractures |
12 |
|
tuberculosis |
12 |
|
chronic liver disease |
11 |
|
cirrhosis |
11 |
|
clinical vertebral fractures |
11 |
|
effectiveness |
11 |
|
graves disease |
11 |
|
hepatocellular carcinoma |
11 |
|
hip fractures |
11 |
|
hyperthyroidism |
11 |
|
hypothyroidism |
11 |
|
myocarditis |
11 |
|
omicron |
11 |
|
pasc |
11 |
|
pericarditis |
11 |
|
post-covid-19 syndrome |
11 |
|
thyroid dysfunction |
11 |
|
upper limb fractures |
11 |
|
adverse events |
10 |
|
atrial fibrillation |
10 |
|
autoimmune disorders |
10 |
|
delirium |
10 |
|
dementia |
10 |
|
incident cvd |
10 |
|
ischemic stroke |
10 |
|
major adverse cardiovascular events |
10 |
|
post-acute sequelae of sars-cov-2 |
10 |
|
post-covid cvd |
10 |
|
sex difference |
10 |
|
adverse events of special interest (aesi) |
9 |
|
cancer |
9 |
|
cardiovascular complications |
9 |
|
heart failure |
9 |
|
infection |
9 |
|
microvascular complications |
9 |
|
molnupiravir |
9 |
|
nirmatrelvir-ritonavir |
9 |
|
pediatrics |
9 |
|
pharmacovigilance |
9 |
|
public health |
9 |
|
safety |
9 |
|
vaccine |
9 |
|
viral disease |
9 |
|
waning vaccine effectiveness |
9 |
|
adverse events of special interest |
8 |
|
age-specific association |
8 |
|
antivirals |
8 |
|
biological sciences |
8 |
|
ckd |
8 |
|
diabetes mellitus |
8 |
|
ehr |
8 |
|
emulated trial |
8 |
|
geriatrics |
8 |
|
health sciences |
8 |
|
mrna vaccine |
8 |
|
multiple organ complications |
8 |
|
myocardial infarction |
8 |
|
pediatric population |
8 |
|
population-based |
8 |
|
primary health care |
8 |
|
severity |
8 |
|
antiviral medications |
7 |
|
chronic disease |
7 |
|
cohort study |
7 |
|
depression |
7 |
|
diabetes complications |
7 |
|
efficacy |
7 |
|
general practice |
7 |
|
hong kong |
7 |
|
hospitalisation |
7 |
|
mental disorders |
7 |
|
older people |
7 |
|
post-complication mortality |
7 |
|
stroke |
7 |
|
vaccination |
7 |
|
pharmacoepidemiology |
6 |
|
real-world evidence |
6 |
|
type 2 diabetes |
6 |
|
all-cause mortality |
5 |
|
chinese |
5 |
|
covid |
5 |
|
healthcare expenditure |
5 |
|
inactivated vaccines |
5 |
|
observational study |
5 |
|
systematic review |
5 |
|
cancer epidemiology |
4 |
|
comorbidity |
4 |
|
drug safety |
4 |
|
long-term care |
4 |
|
prolactin |
4 |
|
psychotic disorders |
4 |
|
adolescents |
3 |
|
health equity |
3 |
|
machine learning |
3 |
|
major depressive disorder |
3 |
|
males |
3 |
|
multiple chronic conditions |
3 |
|
older adults |
3 |
|
population health |
3 |
|
public mental health |
3 |
|
social epidemiology |
3 |
|
activities of daily living |
2 |
|
cardiovascular diseases |
2 |
|
clustering |
2 |
|
daily routines |
2 |
|
everyday life |
2 |
|
health behavior |
2 |
|
inclusive education |
2 |
|
medical comorbidity |
2 |
|
mental health |
2 |
|
obesity |
2 |
|
problematic internet use |
2 |
|
regularity |
2 |
|
resilience |
2 |
|
teacher efficacy |
2 |
|
abdominal obesity |
1 |
|
age-period-cohort |
1 |
|
ageing |
1 |
|
aging |
1 |
|
antidepressant |
1 |
|
asia |
1 |
|
asian |
1 |
|
beers criteria |
1 |
|
benzodiazepines |
1 |
|
bibliometric analysis |
1 |
|
biostatistics |
1 |
|
birth cohort effect |
1 |
|
cardiometabolic diseases |
1 |
|
cerebrovascular disease |
1 |
|
chronic di |
1 |
|
cohort effect |
1 |
|
cohort studies |
1 |
|
colorectal cancer |
1 |
|
community psychiatry |
1 |
|
community trends |
1 |
|
comparative study |
1 |
|
contact tracing |
1 |
|
copd |
1 |
|
decision tree model |
1 |
|
delivery of healthcare |
1 |
|
deprivation |
1 |
|
dispersion |
1 |
|
economic development |
1 |
|
education |
1 |
|
epidemiology of chronic diseases |
1 |
|
erectile dysfunction |
1 |
|
gender |
1 |
|
general obesity |
1 |
|
geriatric medicine |
1 |
|
health & safety |
1 |
|
health inequalities |
1 |
|
hong kong-specific criteria |
1 |
|
hospitalization |
1 |
|
housing |
1 |
|
incidence |
1 |
|
income |
1 |
|
inequalities |
1 |
|
inequality |
1 |
|
inpatients |
1 |
|
international |
1 |
|
linear mixed model |
1 |
|
log-linear modeling |
1 |
|
mental disorder |
1 |
|
middle aged |
1 |
|
motives for smoking cessation |
1 |
|
non-communicable disease |
1 |
|
normative internet use |
1 |
|
occupational groups |
1 |
|
one-year abstinence |
1 |
|
osteoporosis |
1 |
|
pattern of internet use |
1 |
|
peers' norm |
1 |
|
population aging |
1 |
|
potentially inappropriate medication |
1 |
|
poverty |
1 |
|
professional development |
1 |
|
prospective studies |
1 |
|
psychiatric comorbidity |
1 |
|
psychopharmacology |
1 |
|
rasch model |
1 |
|
rasch rating scale model |
1 |
|
schizophrenia |
1 |
|
school psychosocial environment |
1 |
|
screening |
1 |
|
sedative-hypnotics |
1 |
|
smoking |
1 |
|
socio-economic |
1 |
|
socioeconomic background |
1 |
|
socioeconomic development |
1 |
|
socioeconomic factors |
1 |
|
socioeconomic status |
1 |
|
special educational needs |
1 |
|
superspreading |
1 |
|
unlinked |
1 |
|
western |
1 |
|
z-drugs |
1 |
